1. Home
  2. UTF vs GLSI Comparison

UTF vs GLSI Comparison

Compare UTF & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Infrastructure Fund Inc

UTF

Cohen & Steers Infrastructure Fund Inc

HOLD

Current Price

$26.86

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$26.74

Market Cap

123.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTF
GLSI
Founded
2004
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
123.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
UTF
GLSI
Price
$26.86
$26.74
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$50.00
AVG Volume (30 Days)
171.7K
639.1K
Earning Date
01-01-0001
11-14-2025
Dividend Yield
7.19%
N/A
EPS Growth
N/A
N/A
EPS
2.84
N/A
Revenue
$138,636,669.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.16
N/A
Revenue Growth
19.80
N/A
52 Week Low
$22.05
$7.78
52 Week High
$26.53
$34.10

Technical Indicators

Market Signals
Indicator
UTF
GLSI
Relative Strength Index (RSI) 81.58 50.41
Support Level $25.84 $25.68
Resistance Level $26.27 $30.13
Average True Range (ATR) 0.25 3.14
MACD 0.05 -0.80
Stochastic Oscillator 97.86 20.84

Price Performance

Historical Comparison
UTF
GLSI

About UTF Cohen & Steers Infrastructure Fund Inc

Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: